Vimarsana
Biggest News Aggregation in the World

Page 11 - Adaptive Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adaptive Research Today - Breaking & Trending Today

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial - Vimarsana News

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial

Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With GlioblastomaLARKSPUR, Calif.--(BUSINESS WIRE)--#GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and V...

Kazia Therapeutics reports good half-year progress despite market challenges - Vimarsana News

Kazia Therapeutics reports good half-year progress despite market challenges

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies.

Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma - Vimarsana News

Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma

Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Some of the significant benefits of FTD include:

Kintara Therapeutics Granted Fast Track Designation For VAL-083 - Vimarsana News

Kintara Therapeutics Granted Fast Track Designation For VAL-083

(RTTNews) - Kintara Therapeutics, Inc. (KTRA) announced FDA has granted Fast Track Designation to VAL-083 for the treatment of patients with newly...

Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study - Vimarsana News

Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe.